Genentech Terminates Collaboration Agreement With Xencor

Dow Jones

Mar 10

By Elias Schisgall

F. Hoffmann-La Roche subsidiary Genentech terminated its collaboration agreement with Xencor effective Sept. 4.

Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for convenience, Xencor said in a Securities and Exchange Commission filing on Monday.

Roche announced in January 2025 that it was removing the sole active collaboration product covered by the agreement, an engineered protein called efbalropendekin alfa, from its development pipeline. Xencor had expected Genentech to terminate the agreement, the company said Monday.

Xencor had ceased all cost-sharing development activities by opting out of co-development under the agreement in the first half of 2024, it said. At that point, Genentech assumed sole responsibility for certain products covered by the collaboration agreement, including efbalropendekin alfa.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 09, 2026 16:19 ET (20:19 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2618447674"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618447674\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618447674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618447674","market":"nz","top_or_hot":-1,"title":"Genentech Terminates Collaboration Agreement With Xencor","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  F. Hoffmann-La Roche subsidiary Genentech terminated its collaboration agreement with Xencor effective Sept. 4. \n</p>\n<p>\n  Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for convenience, Xencor said in a Securities and Exchange Commission filing on Monday. \n</p>\n<p>\n  Roche announced in January 2025 that it was removing the sole active collaboration product covered by the agreement, an engineered protein called efbalropendekin alfa, from its development pipeline. Xencor had expected Genentech to terminate the agreement, the company said Monday. \n</p>\n<p>\n  Xencor had ceased all cost-sharing development activities by opting out of co-development under the agreement in the first half of 2024, it said. At that point, Genentech assumed sole responsibility for certain products covered by the collaboration agreement, including efbalropendekin alfa. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 16:19 ET (20:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genentech Terminates Collaboration Agreement With Xencor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenentech Terminates Collaboration Agreement With Xencor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-10 04:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  F. Hoffmann-La Roche subsidiary Genentech terminated its collaboration agreement with Xencor effective Sept. 4. \n</p>\n<p>\n  Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for convenience, Xencor said in a Securities and Exchange Commission filing on Monday. \n</p>\n<p>\n  Roche announced in January 2025 that it was removing the sole active collaboration product covered by the agreement, an engineered protein called efbalropendekin alfa, from its development pipeline. Xencor had expected Genentech to terminate the agreement, the company said Monday. \n</p>\n<p>\n  Xencor had ceased all cost-sharing development activities by opting out of co-development under the agreement in the first half of 2024, it said. At that point, Genentech assumed sole responsibility for certain products covered by the collaboration agreement, including efbalropendekin alfa. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 16:19 ET (20:19 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618447674","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618447674","pubTimestamp":1773087540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"F. Hoffmann-La Roche subsidiary Genentech terminated its collaboration agreement with Xencor effective Sept. 4.Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for convenience, Xencor said in a Securities and Exchange Commission filing on Monday.Roche announced in January 2025 that it was removing the sole active collaboration product covered by the agreement, an engineered protein called efbalropendekin alfa, from its development pipeline. Xencor had expected Genentech to terminate the agreement, the company said Monday.Xencor had ceased all cost-sharing development activities by opting out of co-development under the agreement in the first half of 2024, it said. At that point, Genentech assumed sole responsibility for certain products covered by the collaboration agreement, including efbalropendekin alfa.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XNCR":"Xencor Inc"},"translate_title":"基因泰克终止与Xencor的合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XNCR":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  F. Hoffmann-La Roche subsidiary Genentech terminated its collaboration agreement with Xencor effective Sept. 4. \n\n\n  Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for convenience, Xencor said in a Securities and Exchange Commission filing on Monday. \n\n\n  Roche announced in January 2025 that it was removing the sole active collaboration product covered by the agreement, an engineered protein called efbalropendekin alfa, from its development pipeline. Xencor had expected Genentech to terminate the agreement, the company said Monday. \n\n\n  Xencor had ceased all cost-sharing development activities by opting out of co-development under the agreement in the first half of 2024, it said. At that point, Genentech assumed sole responsibility for certain products covered by the collaboration agreement, including efbalropendekin alfa. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 16:19 ET (20:19 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}